Paelinck, L.; Dept. of Radiation Oncology, Ghent University Hospital, Belgium
GULYBAN, Akos ; Dept. of Radiation Oncology, Liège University Hospital, Belgium
Lakosi, F.; Dept. of Radiation Oncology, Liège University Hospital, Belgium
Vercauteren, T.; Dept. of Radiation Oncology, Ghent University Hospital, Belgium
De Gersem, W.; Dept. of Radiation Oncology, Ghent University Hospital, Belgium, Dept. of Radiotherapy and Experimental Cancer Research, Ghent University, Belgium
Speleers, B.; Dept. of Radiotherapy and Experimental Cancer Research, Ghent University, Belgium
Monten, C.; Dept. of Radiation Oncology, Ghent University Hospital, Belgium, Dept. of Radiotherapy and Experimental Cancer Research, Ghent University, Belgium
Mulliez, T.; Dept. of Radiation Oncology, Ghent University Hospital, Belgium
Berkovic, P.; Dept. of Radiation Oncology, Liège University Hospital, Belgium
van Greveling, A.; Dept. of Radiation Oncology, Ghent University Hospital, Belgium
Decoster, F.; Dept. of Radiation Oncology, Ghent University Hospital, Belgium
Coucke, Philippe ; Université de Liège - ULiège > Département des sciences cliniques > Radiothérapie
De Neve, W.; Dept. of Radiation Oncology, Ghent University Hospital, Belgium, Dept. of Radiotherapy and Experimental Cancer Research, Ghent University, Belgium
Veldeman, L.; Dept. of Radiation Oncology, Ghent University Hospital, Belgium, Dept. of Radiotherapy and Experimental Cancer Research, Ghent University, Belgium
[1] Haviland, J.S., Owen, J.R., Dewar, J.A., Agrawal, R.K., Barrett, J., Barrett-Lee, P.J., et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 14 (2013), 1086–1094.
[2] Whelan, T.J., Pignol, J.P., Levine, M.N., Julian, J.A., MacKenzie, R., Parpia, S., et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 362 (2010), 513–520.
[3] Bartelink, H., Maingon, P., Poortmans, P., Weltens, C., Fourquet, A., Jager, J., et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol 16 (2015), 47–56.
[4] Aly, M.M., Abo-Madyan, Y., Jahnke, L., Wenz, F., Glatting, G., Comparison of breast sequential and simultaneous integrated boost using the biologically effective dose volume histogram (BEDVH). Radiat Oncol, 11, 2016, 16.
[5] Van Parijs, H., Reynders, T., Heuninckx, K., Verellen, D., Storme, G., De Ridder, M., Breast conserving treatment for breast cancer: dosimetric comparison of sequential versus simultaneous integrated photon boost. Biomed Res Int, 2014, 2014, 827475.
[6] Singla, R., King, S., Albuquerque, K., Creech, S., Dogan, N., Simultaneous-integrated boost intensity-modulated radiation therapy (SIB-IMRT) in the treatment of early-stage left-sided breast carcinoma. Med Dosim 31 (2006), 190–196.
[7] Guerrero, M., Li, X.A., Earl, M.A., Sarfaraz, M., Kiggundu, E., Simultaneous integrated boost for breast cancer using IMRT: a radiobiological and treatment planning study. Int J Radiat Oncol Biol Phys 59 (2004), 1513–1522.
[8] Lansu, J.T., Essers, M., Voogd, A.C., Luiten, E.J., Buijs, C., Groenendaal, N., et al. The influence of simultaneous integrated boost, hypofractionation and oncoplastic surgery on cosmetic outcome and PROMs after breast conserving therapy. Eur J Surg Oncol 41 (2015), 1411–1416.
[9] Raiyawa, T., Lertbutsayanukul, C., Rojpornpradit, P., Late effects and cosmetic results of simultaneous integrated boost versus sequential boost after conventional irradiation in breast-conserving therapy; out come of 7 months follow-up. J Med Assoc Thai 92 (2009), 390–397.
[10] Scorsetti, M., Alongi, F., Fogliata, A., Pentimalli, S., Navarria, P., Lobefalo, F., et al. Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments. Radiat Oncol, 7, 2012, 145.
[11] Dellas, K., Vonthein, R., Zimmer, J., Dinges, S., Boicev, A.D., Andreas, P., et al. Hypofractionation with simultaneous integrated boost for early breast cancer: results of the German multicenter phase II trial (ARO-2010-01). Strahlenther Onkol 190 (2014), 646–653.
[12] Van Parijs, H., Miedema, G., Vinh-Hung, V., Verbanck, S., Adriaenssens, N., Kerkhove, D., et al. Short course radiotherapy with simultaneous integrated boost for stage I-II breast cancer, early toxicities of a randomized clinical trial. Radiat Oncol, 7, 2012, 80.
[13] Cooper, B.T., Formenti-Ujlaki, G.F., Li, X., Shin, S.M., Fenton-Kerimian, M., Guth, A., et al. Prospective randomized trial of prone accelerated intensity modulated breast radiation therapy with a daily versus weekly boost to the tumor bed. Int J Radiat Oncol Biol Phys 95 (2016), 571–578.
[14] Bantema-Joppe, E.J., Vredeveld, E.J., de Bock, G.H., Busz, D.M., Woltman-van Iersel, M., Dolsma, W.V., et al. Five year outcomes of hypofractionated simultaneous integrated boost irradiation in breast conserving therapy; patterns of recurrence. Radiother Oncol 108 (2013), 269–272.
[15] Osa, E.O., DeWyngaert, K., Roses, D., Speyer, J., Guth, A., Axelrod, D., et al. Prone breast intensity modulated radiation therapy: 5-year results. Int J Radiat Oncol Biol Phys 89 (2014), 899–906.
[16] Kirby, A.M., Evans, P.M., Donovan, E.M., Convery, H.M., Haviland, J.S., Yarnold, J.R., Prone versus supine positioning for whole and partial-breast radiotherapy: a comparison of non-target tissue dosimetry. Radiother Oncol 96 (2010), 178–184.
[17] Lymberis, S.C., Dewyngaert, J.K., Parhar, P., Chhabra, A.M., Fenton-Kerimian, M., Chang, J., et al. Prospective assessment of optimal individual position (prone versus supine) for breast radiotherapy: volumetric and dosimetric correlations in 100 patients. Int J Radiat Oncol Biol Phys 84 (2012), 902–909.
[18] Formenti, S.C., DeWyngaert, J.K., Jozsef, G., Goldberg, J.D., Prone vs supine positioning for breast cancer radiotherapy. JAMA 308 (2012), 861–863.
[19] Mulliez, T., Veldeman, L., van Greveling, A., Speleers, B., Sadeghi, S., Berwouts, D., et al. Hypofractionated whole breast irradiation for patients with large breasts: a randomized trial comparing prone and supine positions. Radiother Oncol 108 (2013), 203–208.
[20] Mulliez, T., Veldeman, L., Speleers, B., Mahjoubi, K., Remouchamps, V., Van Greveling, A., et al. Heart dose reduction by prone deep inspiration breath hold in left-sided breast irradiation. Radiother Oncol 114 (2015), 79–84.
[21] Veldeman, L., Speleers, B., Bakker, M., Jacobs, F., Coghe, M., De Gersem, W., et al. Preliminary results on setup precision of prone-lateral patient positioning for whole breast irradiation. Int J Radiat Oncol Biol Phys 78 (2010), 111–118.
[22] Mulliez, T., Speleers, B., Madani, I., De Gersem, W., Veldeman, L., De Neve, W., Whole breast radiotherapy in prone and supine position: is there a place for multi-beam IMRT?. Radiat Oncol, 8, 2013, 151.
[23] Vercauteren, T., De Gersem, W., Olteanu, L.A., Madani, I., Duprez, F., Berwouts, D., et al. Deformation field validation and inversion applied to adaptive radiation therapy. Phys Med Biol 58 (2013), 5269–5286.
[24] Holland, R., Veling, S.H., Mravunac, M., Hendriks, J.H., Histologic multifocality of Tis, T1–2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer 56 (1985), 979–990.
[25] Yarnold, J., Ashton, A., Bliss, J., Homewood, J., Harper, C., Hanson, J., et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol 75 (2005), 9–17.
[26] McDonald, M.W., Godette, K.D., Whitaker, D.J., Davis, L.W., Johnstone, P.A., Three-year outcomes of breast intensity-modulated radiation therapy with simultaneous integrated boost. Int J Radiat Oncol Biol Phys 77 (2009), 523–530.
[27] Bantema-Joppe, E.J., Schilstra, C., de Bock, G.H., Dolsma, W.V., Busz, D.M., Langendijk, J.A., et al. Simultaneous integrated boost irradiation after breast-conserving surgery: physician-rated toxicity and cosmetic outcome at 30 months' follow-up. Int J Radiat Oncol Biol Phys 83 (2012), e471–e477.
[28] Fiorentino, A., Mazzola, R., Ricchetti, F., Giaj Levra, N., Fersino, S., Naccarato, S., et al. Intensity modulated radiation therapy with simultaneous integrated boost in early breast cancer irradiation. Report of feasibility and preliminary toxicity. Cancer Radiother 19 (2015), 289–294.
[29] Lee, H.C., Kim, S.H., Suh, Y.J., Chung, M.J., Kang, D.G., Choi, H.J., et al. A prospective cohort study on postoperative radiotherapy with TomoDirect using simultaneous integrated boost technique in early breast cancer. Radiat Oncol, 9, 2014, 244.
[30] Alford, S.L., Prassas, G.N., Vogelesang, C.R., Leggett, H.J., Hamilton, C.S., Adjuvant breast radiotherapy using a simultaneous integrated boost: clinical and dosimetric perspectives. J Med Imaging Radiat Oncol 57 (2013), 222–229.
[31] Ghannam, A.A., Khedr, R.A., An accelerated hypofractionated schedule with a daily concomitant boost after breast conservation surgery: the feasibility and toxicity. J Egypt Natl Cancer Inst 28 (2016), 39–44.
[32] Finkel, M.A., Cooper, B.T., Li, X., Fenton-Kerimian, M., Goldberg, J.D., Formenti, S.C., Quality of life in women undergoing breast irradiation in a randomized, controlled clinical trial evaluating different tumor bed boost fractionations. Int J Radiat Oncol Biol Phys 95 (2016), 579–589.
